Skip to main content
SpringerLink
Log in

Immunoplasticity in cutaneous melanoma: beyond pure morphology

  • Review and Perspectives
  • Published:
Virchows Archiv Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig 1
Fig. 2
Fig. 3

References

  1. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Jäger N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, López-Otín C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdés-Mas R, van Buuren MM, van’t Veer L, Vincent-Salomon A, Waddell N, Yates LR (2013) Australian pancreatic cancer genome initiative; ICGC breast cancer consortium; ICGC MMML-seq consortium; ICGC PedBrain, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR. Signatures of mutational processes in human cancer. Nature 500(7463):415–421. doi:10.1038/nature12477

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Bastian BC (2014) The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol 9:239–271

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14(10):1014–1022

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Bae JM, Choi YY, Kim DS, Lee JH, Jang HS, Lee JH, Kim H, Oh BH, Roh MR, Nam KA, Chung KY (2015) Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 72(1):59–70

    Article  PubMed  Google Scholar 

  5. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, Bruneval P, Fridman WH, Becker C, Pagès F, Speicher MR, Trajanoski Z, Galon J (2013) Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39(4):782–795

    Article  CAS  PubMed  Google Scholar 

  6. Lee N, Zakka LR, Mihm MC Jr, Schatton T (2016) Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology 48(2):177–187

    Article  PubMed  Google Scholar 

  7. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77(7):1303–1310

    Article  CAS  PubMed  Google Scholar 

  8. Mihm MC Jr, Clemente CG, Cascinelli N (1996) Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Investig 74(1):43–47

    PubMed  Google Scholar 

  9. Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, Saw RP, Thompson JF (2012) Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 30(21):2678–2683

    Article  PubMed  Google Scholar 

  10. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960–1964

    Article  CAS  PubMed  Google Scholar 

  11. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD (2015) Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in Unresectable or metastatic melanoma. J Clin Oncol 33(17):1889–1894

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Sullivan RJ, Flaherty KT (2015 Nov) Anti-PD-1 therapies—a new firstline option in advanced melanoma. Nat Rev Clin Oncol 12(11):625–626

    Article  CAS  PubMed  Google Scholar 

  13. Ribas A, Flaherty KT (2015) Gauging the long-term benefits of ipilimumab in melanoma. J Clin Oncol 33(17):1865–1866

    Article  PubMed  Google Scholar 

  14. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C7, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C. Association of Pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315[15]:1600–1609.

  15. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320–330

    Article  CAS  PubMed  Google Scholar 

  16. Orloff M, Weight R, Valsecchi ME, Sato T (2016) Immune check point inhibitors combination in melanoma: worth the toxicity? Rev Recent Clin Trials 11(2):81–86

    Article  CAS  PubMed  Google Scholar 

  17. Spain L, Larkin J (2016) Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. Expert Opin Biol Ther 16(3):389–396. doi:10.1517/14712598.2016.1141195

    Article  CAS  PubMed  Google Scholar 

  18. Grimaldi AM, Marincola FM, Ascierto PA (2016 Apr) Single versus combination immunotherapy drug treatment in melanoma. Expert Opin Biol Ther 16(4):433–441

    Article  CAS  PubMed  Google Scholar 

  19. Teixido C, Gonzalez-Cao M, Karachaliou N, Rosell R (2015) Predictive factors for immunotherapy in melanoma. Ann Transl Med 3(15):208–218

    PubMed  PubMed Central  Google Scholar 

  20. Spits H, Cupedo T (2012) Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu Rev Immunol 30:647–675

    Article  CAS  PubMed  Google Scholar 

  21. Gomez de Agüero M, Ganal-Vonarburg SC, Fuhrer T, Rupp S, Uchimura Y, Li H, Steinert A, Heikenwalder M, Hapfelmeier S, Sauer U, McCoy KD, Macpherson AJ (2016) The maternal microbiota drives early postnatal innate immune development. Science 351:1296–1302

    Article  PubMed  CAS  Google Scholar 

  22. Duffin R, O’Connor RA, Crittenden S, Forster T, Yu C, Zheng X, Smyth D, Robb CT, Rossi F, Skouras C, Tang S, Richards J, Pellicoro A, Weller RB, Breyer RM, Mole DJ, Iredale JP, Anderton SM, Narumiya S, Maizels RM, Ghazal P, Howie SE, Rossi AG, Yao C (2016) Prostaglandin E2 constrains systemic inflammation through an innate lymphoid cell–IL-22 axis. Science 351:1333–1338

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Carrega P, Loiacono F, Di Carlo E, Scaramuccia A, Mora M, Conte R, Benelli R, Spaggiari GM, Cantoni C, Campana S, Bonaccorsi I, Morandi B, Truini M, Mingari MC, Moretta L, Ferlazzo G (2015) NCR[+]ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures. Nat Commun 6:8280

    Article  CAS  PubMed  Google Scholar 

  24. Viant C, Rankin LC, Girard-Madoux MJH, Seillet C, Shi W, Smyth MJ, Bartholin L, Walzer T, Huntington ND, Vivier E, Belz GT (2016) Transforming growth factor–β and notch ligands act as opposing environmental cues in regulating the plasticity of type 3 innate lymphoid cells. Sci Signal 9:ra46

    Article  PubMed  CAS  Google Scholar 

  25. Fišerová A, Richter J, Čapková K, Bieblová J, Mikyšková R, Reiniš M, Indrová M (2016) Resistance of novel mouse strains different in MHC class I and the NKC domain to the development of experimental tumors. Int J Oncol 3

  26. Tallerico R, Garofalo C, Carbone E (2016) A new biological feature of natural killer cells: the recognition of solid tumor-derived cancer stem cells. Front Immunol 7:179

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Tarazona R, Duran E, Solana R (2016) Natural killer cell recognition of melanoma: new clues for a more effective immunotherapy. Front Immunol 6:649

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Kitamura T, Qian BZ, Pollard JW (2015) Immune cell promotion of metastasis. Nat Rev Immunol 15(2):73–86

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Groh V, Wu J, Yee C, Spies T (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734–738

    Article  CAS  PubMed  Google Scholar 

  30. Waldhauer I, Steinle A (2006) Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 66:2520–2526

    Article  CAS  PubMed  Google Scholar 

  31. Fremd C, Schuetz F, Sohn C, Beckhove P, Domschke C (2013) B cell-regulated immune responses in tumor models and cancer patients. Oncoimmunology 2(7):e25443

    Article  PubMed  PubMed Central  Google Scholar 

  32. Iglesia MD, Parker JS, Hoadley KA, Serody JS, Perou CM, Vincent BG (2016) Genomic analysis of immune cell infiltrates across 11 tumor types. J Natl Cancer Inst 108(11):pii: djw144. doi:10.1093/jnci/djw144

    Article  Google Scholar 

  33. Garg K, Maurer M, Griss J, Brüggen MC, Wolf IH, Wagner C, Willi N, Mertz KD, Wagner SN (2016) Tumor associated B cells in cutaneous primary melanoma and improved clinical outcome. Hum Pathol

  34. Ladányi A, Kiss J, Mohos A, Somlai B, Liszkay G, Gilde K, Fejös Z, Gaudi I, Dobos J, Tímár J (2011) Prognostic impact of B-cell density in cutaneous melanoma. Cancer Immunol Immunother 60(12):1729–1738

    Article  PubMed  CAS  Google Scholar 

  35. Ladányi A (2015) Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma. Pigment Cell Melanoma Res

  36. Martinez-Rodriguez M, Thompson AK, Monteagudo C (2014) A significant percentage of CD20-positive TILs correlates with poor prognosis in patients with primary cutaneous malignant melanoma. Histopathology 65(5):726–728

    Article  PubMed  Google Scholar 

  37. Weissmann A, Roses DF, Harris MN, Dubin N (1984) Prediction of lymph node metastases from the histologic features of primary cutaneous malignant melanomas. Am J Dermatopathol 6(Suppl):35–41

    PubMed  Google Scholar 

  38. Mascaro JM, Molgo M, Castel T, Castro J (1987) Plasma cells within the infiltrate of primary cutaneous malignant melanoma of the skin. A confirmation of its histoprognostic value. Am J Dermatopathol 9(6):497–499

    Article  CAS  PubMed  Google Scholar 

  39. Bosisio FM, Wilmott JS, Volders N, Mercier M, Wouters J, Stas M, Blokx WA, Massi D, Thompson JF, Scolyer RA, van Baren N, van den Oord JJ (2016) Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. Mod Pathol 29(4):347–358

    Article  CAS  PubMed  Google Scholar 

  40. Khan AR, Hams E, Floudas A, Sparwasser T, Weaver CT, Fallon PG (2015) PD-L1hi B cells are critical regulators of humoral immunity. Nat Commun 6:5997

    Article  CAS  PubMed  Google Scholar 

  41. Germain C, Gnjatic S, Dieu-Nosjean MC (2015) Tertiary lymphoid structure-associated B cells are key players in anti-tumor immunity. Front Immunol 6:67

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Dieu-Nosjean MC, Goc J, Giraldo NA, Sautès-Fridman C, Fridman WH (2014) Tertiary lymphoid structures in cancer and beyond. Trends Immunol 35(11):571–580

    Article  CAS  PubMed  Google Scholar 

  43. Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12:298–306

    Article  CAS  PubMed  Google Scholar 

  44. Barros MH, Hauck F, Dreyer JH, Kempkes B, Niedobitek G (2013) Macrophage polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages. PLoS One 8(11):e80908. doi:10.1371/journal.pone.0080908 eCollection 2013

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  45. Pucci F, Garris C, Lai CP, Newton A, Pfirschke C, Engblom C, Alvarez D, Sprachman M, Evavold C, Magnuson A, von Andrian UH, Glatz K, Breakefield XO, Mempel TR, Weissleder R, Pittet MJ (2016) SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science 352(6282):242–246

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Bulman A, Neagu M, Constantin C (2013) Immunomics in skin cancer—improvement in diagnosis, prognosis and therapy monitoring. Curr Proteomics 10(3):202–217

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Fridman WH, Remark R, Goc J, Giraldo NA, Becht E, Hammond SA, Damotte D, Dieu-Nosjean MC, Sautès-Fridman C (2014) The immune microenvironment: a major player in human cancers. Int Arch Allergy Immunol 164(1):13–26

    CAS  PubMed  Google Scholar 

  48. Riesenberg S, Groetchen A, Siddaway R, Bald T, Reinhardt J, Smorra D, Kohlmeyer J, Renn M, Phung B, Aymans P, Schmidt T, Hornung V, Davidson I, Goding CR, Jönsson G, Landsberg J, Tüting T, Hölzel M (2015) MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. Nat Commun 6:8755

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Smith HA, Kang Y (2013) The metastasis-promoting roles of tumor-associated immune cells. J Mol Med [Berl] 91(4):411–429

    Article  CAS  Google Scholar 

  50. Kemény LV, Kurgyis Z, Buknicz T, Groma G, Jakab Á, Zänker K, Dittmar T, Kemény L, Németh IB (2016) Melanoma cells can adopt the phenotype of stromal fibroblasts and macrophages by spontaneous cell fusion in vitro. Int J Mol Sci 17(6)

  51. Chevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C, Van Gele M, van Geel N, Brochez L (2015 Jan 16) Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma. J Transl Med 13(1):9

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum MD, Daud A, Barber DL, Amigorena S, Van’t Veer LJ, Sperling AI, Wolf DM, Krummel MF (2014) Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26(5):638–652

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Zitvogel L, Kroemer G (2014) CD103+ dendritic cells producing interleukin-12 in anticancer immunosurveillance. Cancer Cell 26(5):591–593

    Article  CAS  PubMed  Google Scholar 

  54. Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, Verstegen NJ, Ciampricotti M, Hawinkels LJ, Jonkers J, de Visser KE (2015) IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522(7556):345–348

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E (2014 May 29) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106(6):dju124

    Article  PubMed  CAS  Google Scholar 

  56. Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, Holland-Letz T, Umansky L, Beckhove P, Sucker A, Schadendorf D, Utikal J, Umansky V (2015) Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin Cancer Res 21(24):5453–5459

    Article  CAS  PubMed  Google Scholar 

  57. Ferrucci PF, Gandini S, Battaglia A, Alfieri S, Di Giacomo AM, Giannarelli D, Cappellini GC, De Galitiis F, Marchetti P, Amato G, Lazzeri A, Pala L, Cocorocchio E, Martinoli C (2015) Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer 112(12):1904–1910

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S (2014) Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A 111(32):11774–11779

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Bald T, Quast T, Landsberg J, Rogava M, Glodde N, Lopez-Ramos D, Kohlmeyer J, Riesenberg S, van den Boorn-Konijnenberg D, Hömig-Hölzel C, Reuten R, Schadow B, Weighardt H, Wenzel D, Helfrich I, Schadendorf D, Bloch W, Bianchi ME, Lugassy C, Barnhill RL, Koch M, Fleischmann BK, Förster I, Kastenmüller W, Kolanus W, Hölzel M, Gaffal E, Tüting T (2014) Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature 507(7490):109–113

    Article  CAS  PubMed  Google Scholar 

  60. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, Diehn M, West RB, Plevritis SK, Alizadeh AA (2015) The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 21(8):938–945

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Hussein MR, Elsers DAH, Fadel SA, Omar AEM (2006) Immunohistological characterization of tumour infiltrating lymphocytes in melanocytic skin lesions. J Clin Pathol 59:316–324

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Kim J, Ryu SJ, Oh K, Ju JM, Jeon JY, Nam G, Lee DS, Kim HR, Kim JY, Chang J, Sproule T, Choi K, Roopenian D, Choi EY (2015) Memory programming in CD8[+] T-cell differentiation is intrinsic and is not determined by CD4 help. Nat Commun 6:7994

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Shklovskaya E, Terry AM, Guy TV, Buckley A, Bolton HA, Zhu E, Holst J, Fazekas de St Groth B (2016) Tumour-specific CD4 T cells eradicate melanoma via indirect recognition of tumour-derived antigen. Immunol Cell Biol

  64. Fonteneau JF, Brilot F, Münz C, Gannagé M (2016) The tumor antigen NY-ESO-1 mediates direct recognition of melanoma cells by CD4+ T cells after intercellular antigen transfer. J Immunol 196(1):64–71

    Article  CAS  PubMed  Google Scholar 

  65. Balkwill FR, Capasso M, Hagemann T (2012) The tumor microenvironment at a glance. J Cell Sci 125(Pt 23):5591–5596

    Article  CAS  PubMed  Google Scholar 

  66. Feng Y, van der Veeken J, Shugay M, Putintseva EV, Osmanbeyoglu HU, Dikiy S, Hoyos BE, Moltedo B, Hemmers S, Treuting P, Leslie CS, Chudakov DM, Rudensky AY (2015) A mechanism for expansion of regulatory T-cell repertoire and its role in self-tolerance. Nature 528(7580):132–136

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Bruno TC, French JD, Jordan KR, Ramirez O, Sippel TR, Borges VF, Haugen BR, McCarter MD, Waziri A, Slansky JE (2013) Influence of human immune cells on cancer: studies at the University of Colorado. Immunol Res 55(1–3):22–33

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Bothur E, Raifer H, Haftmann C, Stittrich AB, Brüstle A, Brenner D, Bollig N, Bieringer M, Kang CH, Reinhard K, Camara B, Huber M, Visekruna A, Steinhoff U, Repenning A, Bauer UM, Sexl V, Radbruch A, Sparwasser T, Mashreghi MF, Wah Mak T, Lohoff M (2015) Antigen receptor-mediated depletion of FOXP3 in induced regulatory T-lymphocytes via PTPN2 and FOXO1. Nat Commun 6:8576

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Kim JM, Chen DS (2016) Immune-escape to PD-L1/PD-1 blockade: 7 steps to success [or failure]. Ann Oncol

  70. Yoon JH, Sudo K, Kuroda M, Kato M, Lee IK, Han JS, Nakae S, Imamura T, Kim J, Ju JH, Kim DK, Matsuzaki K, Weinstein M, Matsumoto I, Sumida T, Mamura M (2015) Phosphorylation status determines the opposing functions of Smad2/Smad3 as STAT3 cofactors in TH17 differentiation. Nat Commun 6:7600

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pagès F, Galon J (2011) Clinical impact of different classes of infiltrating T cytotoxic and helper cells [Th1, th2, treg, th17] in patients with colorectal cancer. Cancer Res 71(4):1263–1271

    Article  CAS  PubMed  Google Scholar 

  72. Hillen F, Baeten CIM, van de Winkel A, Creytens D, van der Schaft DWJ, Winnepenninckx V, Griffioen AW (2008) Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma. Cancer Immunol Immunother 57:97–106

    Article  PubMed  Google Scholar 

  73. Li B, Li T, Pignon JC, Wang B, Wang J, Shukla SA, Dou R, Chen Q, Hodi FS, Choueiri TK, Wu C, Hacohen N, Signoretti S, Liu JS, Liu XS (2016) Landscape of tumor-infiltrating T cell repertoire of human cancers. Nat Genet 48(7):725–732

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Bernsen MR, Diepstra JH, van Mil P, Punt CJ, Figdor CG, van Muijen GN, Adema GJ, Ruiter DJ (2004) Presence and localization of T-cell subsets in relation to melanocyte differentiation antigen expression and tumour regression as assessed by immunohistochemistry and molecular analysis of microdissected T cells. J Pathol 202(1):70–79

    Article  CAS  PubMed  Google Scholar 

  75. Chen L, Flies DB (2013) Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 13(4):227–242. doi:10.1038/nri3405

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  76. Teng MW, Ngiow SF, Ribas A, Smyth MJ (2015) Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 75(11):2139–2145. doi:10.1158/0008-5472.CAN-15-0255

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME et al (2014) PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest 124:2246–2259

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Zheng Y, Zha Y, Spaapen RM, Mathew R, Barr K, Bendelac A, Gajewski TF (2013) Egr2-dependent gene expression profiling and ChIP-seq reveal novel biologic targets in T cell anergy. Mol Immunol 55(3–4):283–291

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G, Fallahi-Sichani M, Dutton-Regester K, Lin JR, Cohen O, Shah P, Lu D, Genshaft AS, Hughes TK, Ziegler CG, Kazer SW, Gaillard A, Kolb KE, Villani AC, Johannessen CM, Andreev AY, Van Allen EM, Bertagnolli M, Sorger PK, Sullivan RJ, Flaherty KT, Frederick DT, Jané-Valbuena J, Yoon CH, Rozenblatt-Rosen O, Shalek AK, Regev A, Garraway LA (2016) Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352(6282):189–196

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Oh YM, Park HB, Shin JH, Lee JE, Park HY, Kho DH, Lee JS, Choi H, Okuda T, Kokame K, Miyata T, Kim IH, Lee SH, Schwartz RH, Choi K (2015) Ndrg1 is a T-cell clonal anergy factor negatively regulated by CD28 costimulation and interleukin-2. Nat Commun 6:8698

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Cipponi A, Wieers G, van Baren N, Coulie PG (2011) Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? Cancer Immunol Immunother 60(8):1153–1160

    Article  PubMed  Google Scholar 

  82. Weiss SA, Han SW, Lui K, Tchack J, Shapiro R, Berman R, Zhong J, Krogsgaard M, Osman I, Darvishian F (2016) Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma. Hum Pathol 57:116–125

    Article  CAS  PubMed  Google Scholar 

  83. Feldmeyer L, Hudgens CW, Lyons GR, Nagarajan P, Aung PP, Curry JL, Torres Cabala CA, Mino B, Rodriguez-Canales J, Reuben A, Chen PL, Ko JS, Billings SD, Bassett RL, Wistuba II, Cooper ZA, Prieto VG, Wargo JA, Tetzlaff MT (2016) Density, distribution, and composition of immune infiltrates correlate with survival in Merkel cell carcinoma. Clin Cancer Res

  84. Laga AC, Zhan Q, Weishaupt C, Ma J, Frank MH (2011) Murphy GF SOX2 and nestin expression in human melanoma: an immunohistochemical and experimental study. Exp Dermatol 20(4):339–345

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Kikuchi E, Yamazaki K, Torigoe T, Cho Y, Miyamoto M, Oizumi S, Hommura F, Dosaka-Akita H, Nishimura M (2007) HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci 98(9):1424–1430

    Article  CAS  PubMed  Google Scholar 

  86. Al-Batran SE, Rafiyan MR, Atmaca A, Neumann A, Karbach J, Bender A, Weidmann E, Altmannsberger HM, Knuth A, Jäger E (2005) Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res 65(9):3937–3941

    Article  CAS  PubMed  Google Scholar 

  87. del Campo AB, Kyte JA, Carretero J, Zinchencko S, Méndez R, González-Aseguinolaza G, Ruiz-Cabello F, Aamdal S, Gaudernack G, Garrido F, Aptsiauri N (2014) Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma. Int J Cancer 134(1):102–113

    Article  PubMed  CAS  Google Scholar 

  88. Garrido F, Algarra I, García-Lora AM (2010) The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible "hard" lesions. Cancer Immunol Immunother 59(10):1601–1606

    Article  CAS  PubMed  Google Scholar 

  89. Chang CC, Pirozzi G, Wen SH, Chung IH, Chiu BL, Errico S, Luongo M, Lombardi ML, Ferrone S (2015) Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy. J Biol Chem 290(44):26562–26575

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Bradley SD, Melendez B, Talukder A, Lizée G (2015) Trouble at the core: BRAF[V600E] drives multiple modes of T-cell suppression in melanoma. Oncoimmunology 5(2):e1078966

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  91. Garrido C, Paco L, Romero I, Berruguilla E, Stefansky J, Collado A, Algarra I, Garrido F, Garcia-Lora AM (2012) MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. Carcinogenesis 33(3):687–693

    Article  CAS  PubMed  Google Scholar 

  92. Buferne M, Chasson L, Grange M, Mas A, Arnoux F, Bertuzzi M, Naquet P, Leserman L, Schmitt-Verhulst AM, Auphan-Anezin N (2015 Mar 6) IFNγ producing CD8+ T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas. Oncoimmunology 4(2):e974959

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  93. Hiltbrunner S, Larssen P, Eldh M, Martinez-Bravo MJ, Wagner AK, Karlsson MC, Gabrielsson S (2016) Exosomal cancer immunotherapy is independent of MHC molecules on exosomes. Oncotarget

  94. Capasso C, Hirvinen M, Garofalo M, Romaniuk D, Kuryk L, Sarvela T, Vitale A, Antopolsky M, Magarkar A, Viitala T, Suutari T, Bunker A, Yliperttula M, Urtti A, Cerullo V (2015 Oct 29) Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma. Oncoimmunology 5(4):e1105429

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  95. Cafri G, Sharbi-Yunger A, Tzehoval E, Alteber Z, Gross T, Vadai E, Margalit A, Gross G, Eisenbach L (2015) mRNA-transfected dendritic cells expressing polypeptides that link MHC-I presentation to constitutive TLR4 activation confer tumor immunity. Mol Ther 23(8):1391–1400

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Compton LA, Murphy GF, Lian CG (2015) Diagnostic immunohistochemistry in cutaneous neoplasia: an update. Dermatopathology [Basel] 2(1):15–42

    Article  Google Scholar 

  97. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C (2014) Ribas Nature

  98. Cimino-Mathews A, Thompson E, Taube JM, Ye X, Lu Y, Meeker A, Xu H, Sharma R, Lecksell K, Cornish TC, Cuka N, Argani P, Emens LA (2016) PD-L1 [B7-H1] expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol 47(1):52–63

    Article  CAS  PubMed  Google Scholar 

  99. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563–567

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, Chen L (2012 Mar 28) Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4(127):127ra37

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  101. Thompson E, Taube JM, Elwood H, Sharma R, Meeker A, Warzecha HN, Argani P, Cimino-Mathews A, Emens LA (2016) The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol 29(3):249–258

    Article  CAS  PubMed  Google Scholar 

  102. Hugo W, Zaretsky JM, Sun L et al (2016) Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165:35–44

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Gandhi L BA, Hui R (2014) MK-3475 [anti-PD-1 monoclonal antibody] for non–small cell lung cancer [NSCLC]L antitumor activity and association with tumor PD-L1 expression. [Abstract]. In: Proceedings of the 105th AnnualMeeting of the American Association for Cancer Research. San Diego, CA. Philadelphia [PA]: AACR; 2014. Abstract nr CT105

  104. Daud AI HO, Ribas A (2014) Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma: correlation of tumor PD-L1 expression with outcome [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; San Diego, CA. Philadelphia [PA]: AACR; Abstract nr CT104

  105. Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM (2016) Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun 7:10582

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Donia M, Kjeldsen JW, Svane IM (2015 Oct 29) The controversial role of TNF in melanoma. Oncoimmunology 5(4):e1107699

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  107. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, Zhang M, Papadopoulos N, Kinzler KW, Vogelstein B, Sears CL, Anders RA, Pardoll DM, Housseau F (2015) The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 5(1):43–51

    Article  CAS  PubMed  Google Scholar 

  108. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, Smyth MJ, Old LJ, Mardis ER, Schreiber RD (2012) Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482(7385):400–404

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, Katsaros D, O’Brien-Jenkins A, Gimotty PA, Coukos G (2008) Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 14(1):28–36

    Article  CAS  PubMed  Google Scholar 

  110. Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, Patterson JW, Slingluff CL Jr (2012) Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 72(5):1070–1080

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Brinkman CC, Iwami D, Hritzo MK, Xiong Y, Ahmad S, Simon T, Hippen KL, Blazar BR, Bromberg JS (2016) Treg engage lymphotoxin beta receptor for afferent lymphatic transendothelial migration. Nat Commun 7:12021

    Article  PubMed  PubMed Central  Google Scholar 

  112. Strønen E, Toebes M, Kelderman S, van Buuren MM, Yang W, van Rooij N, Donia M, Böschen ML, Lund-Johansen F, Olweus J, Schumacher TN (2016 Jun 10) Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 352(6291):1337–1341. doi:10.1126/science.aaf2288

    Article  PubMed  CAS  Google Scholar 

  113. Rosenberg SA, Restifo NP (2015) Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348:62–68

    Article  CAS  PubMed  Google Scholar 

  114. Vasaturo A, Halilovic A, Bol KF, Verweij DI, Blokx WA, Punt CJ, Groenen PJ, van Krieken HJ, Textor J, de Vries IJ, Figdor CG (2016) T cell landscape in a primary melanoma predicts the survival of patients with metastatic disease after their treatment with dendritic cell vaccines. Cancer Res

  115. Loo K, Daud A (2016) Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma. Immunotherapy 8(7):775–784

    Article  CAS  PubMed  Google Scholar 

  116. Koguchi Y, Hoen HM, Bambina SA, Rynning MD, Fuerstenberg RK, Curti BD, Urba WJ, Milburn C, Bahjat FR, Korman AJ, Bahjat KS (2015) Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with Ipilimumab. Cancer Res 75(23):5084–5092

    Article  CAS  PubMed  Google Scholar 

  117. Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O’Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D’Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA (2012 Oct 3) Cancer classification using the immunoscore: a worldwide task force. J Transl Med 10:205

    Article  PubMed  PubMed Central  Google Scholar 

  118. Blank CU, Haanen JB, Ribas A, Schumacher TN (2016) Cancer immunology. The “cancer immunogram”. Science 352(6286):658–660

    Article  CAS  PubMed  Google Scholar 

  119. Mlecnik B, Bindea G, Kirilovsky A, Angell HK, Obenauf AC, Tosolini M, Church SE, Maby P, Vasaturo A, Angelova M, Fredriksen T, Mauger S, Waldner M, Berger A, Speicher MR, Pagès F, Valge-Archer V, Galon J (2016) The tumor microenvironment and immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med 8(327):327ra26

    Article  PubMed  CAS  Google Scholar 

  120. Angell H, Galon J (2013) From the immune contexture to the immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 25:261–267

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Translational Cell and Tissue Research, KUL, Minderbroederstraat 19, 3000, Leuven, Belgium

    Francesca Maria Bosisio & Joost J. van den Oord

  2. Università degli studi di Milano-Bicocca, Milan, Italy

    Francesca Maria Bosisio

Authors
  1. Francesca Maria Bosisio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joost J. van den Oord
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesca Maria Bosisio.

Ethics declarations

Funding

FMB is funded by the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement no. 642295.

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bosisio, F.M., van den Oord, J.J. Immunoplasticity in cutaneous melanoma: beyond pure morphology. Virchows Arch 470, 357–369 (2017). https://doi.org/10.1007/s00428-016-2058-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-016-2058-y

Keywords

Search

Navigation